Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications
Conclusion: Our comprehensive investigation highlights SLC31A1 as a promising biomarker for bladder cancer development, progression, and therapy.PMID:38712735 | DOI:10.1177/03946320241240706 (Source: International Journal of Immunopathology and Pharmacology)
Source: International Journal of Immunopathology and Pharmacology - May 7, 2024 Category: Allergy & Immunology Authors: Yun-Zhi Lin Wei-Hui Liu Yu-Peng Wu Hai Cai Qing-Shui Zheng Yong Wei Ning Xu Xue-Yi Xue Source Type: research
Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer
This study aimed to develop an accurate and non-invasive urine-based gene expression assay, including fibroblast growth factor receptor 3 (FGFR3), homeobox A13 (HOXA13), and polo-like kinase 1 (PLK1), to diagnose non-muscle-invasive bladder cancer (NMIBC) at stages Ta and T1. The samples were acquired from 62 patients with NMIBC, 31 control individuals, and 31 patients with non-cancerous genitourinary tract diseases. The expression levels of three relevant genes were determined using quantitative RT-PCR. In addition, the sensitivity and specificity of the data for these genes were computed. Our results showed that PLK1, HO...
Source: Cancer Control - May 7, 2024 Category: Cancer & Oncology Authors: Sahar Valizadeh Sana Taghiyar Serajedin Vahidi Omid Abazari Mahmood Akhavan Tafti Javad Zavar Reza Source Type: research
Effectiveness and Safety of Extended Lymph Node Dissection during Radical Surgery in Patients with Bladder Cancer: A Meta-Analysis
CONCLUSIONS: Among patients with BC undergoing radical cystectomy, extended lymph node dissection did not have a significant effect on operative time, 90-day readmission rates or postoperative complication rates. Thus, extended lymph node dissection is a safe treatment that does not increase the patient's surgical risk.PMID:38715172 | DOI:10.56434/j.arch.esp.urol.20247703.40 (Source: Archivos Espanoles de Urologia)
Source: Archivos Espanoles de Urologia - May 7, 2024 Category: Urology & Nephrology Authors: Heyi Hu Source Type: research
Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer
This study aimed to develop an accurate and non-invasive urine-based gene expression assay, including fibroblast growth factor receptor 3 (FGFR3), homeobox A13 (HOXA13), and polo-like kinase 1 (PLK1), to diagnose non-muscle-invasive bladder cancer (NMIBC) at stages Ta and T1. The samples were acquired from 62 patients with NMIBC, 31 control individuals, and 31 patients with non-cancerous genitourinary tract diseases. The expression levels of three relevant genes were determined using quantitative RT-PCR. In addition, the sensitivity and specificity of the data for these genes were computed. Our results showed that PLK1, HO...
Source: Biochemical Genetics - May 7, 2024 Category: Genetics & Stem Cells Authors: Sahar Valizadeh Sana Taghiyar Serajedin Vahidi Omid Abazari Mahmood Akhavan Tafti Javad Zavar Reza Source Type: research
Applications of artificial intelligence in urologic oncology
CONCLUSIONS: AI technology is actively being investigated in the field of urological cancers as a tool for diagnosis, prediction of prognosis, and decision-making and is expected to be applied in additional clinical areas soon. Despite technological, legal, and ethical concerns, AI will change the landscape of urological cancer management.PMID:38714511 | PMC:PMC11076794 | DOI:10.4111/icu.20230435 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 7, 2024 Category: Cancer & Oncology Authors: Sahyun Pak Sung Gon Park Jeonghyun Park Sung Tae Cho Young Goo Lee Hanjong Ahn Source Type: research
Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications
Conclusion: Our comprehensive investigation highlights SLC31A1 as a promising biomarker for bladder cancer development, progression, and therapy.PMID:38712735 | DOI:10.1177/03946320241240706 (Source: International Journal of Immunopathology and Pharmacology)
Source: International Journal of Immunopathology and Pharmacology - May 7, 2024 Category: Allergy & Immunology Authors: Yun-Zhi Lin Wei-Hui Liu Yu-Peng Wu Hai Cai Qing-Shui Zheng Yong Wei Ning Xu Xue-Yi Xue Source Type: research
Effectiveness and Safety of Extended Lymph Node Dissection during Radical Surgery in Patients with Bladder Cancer: A Meta-Analysis
CONCLUSIONS: Among patients with BC undergoing radical cystectomy, extended lymph node dissection did not have a significant effect on operative time, 90-day readmission rates or postoperative complication rates. Thus, extended lymph node dissection is a safe treatment that does not increase the patient's surgical risk.PMID:38715172 | DOI:10.56434/j.arch.esp.urol.20247703.40 (Source: Archivos Espanoles de Urologia)
Source: Archivos Espanoles de Urologia - May 7, 2024 Category: Urology & Nephrology Authors: Heyi Hu Source Type: research
The challenge of survivors of gynecological carcinomas: a retrospective study on occurrence of second tumors
ConclusionPatients with gynecological tumors have a significantly higher risk of malignant tumors in other systems compared to ordinary population. It is necessary to be vigilant against subsequent high-risk tumors and tumors with poor prognosis within 5 years of initial diagnosis. (Source: Archives of Gynecology and Obstetrics)
Source: Archives of Gynecology and Obstetrics - May 6, 2024 Category: OBGYN Source Type: research
